RxDoctor Payments Data

Kathleen Toon

Nurse Practitioner · Fort Smith, ARNPI 1083251821

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.9% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,165, more than ten times the $115 reported in 2021. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,574in general payments, 2019–2025

Across 369 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$733
  • Novartis$487
  • AstraZeneca$472
  • Daiichi Sankyo Inc.$449
  • Johnson & Johnson$441
  • Merck$434
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$6,10693%
  • Education$4687%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,574 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$59,498
Medicare patients
355
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$61,528
XareltoRivaroxaban59$46,532
Imatinib Mesylate20$13,707
LinzessLinaclotide13$9,961
Enoxaparin Sodium11$2,287
Anastrozole103$1,726
Letrozole63$1,144
Albuterol Sulfate HfaAlbuterol Sulfate36$845
Potassium Chloride34$729
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$391
Prochlorperazine Maleate46$389
Lidocaine-PrilocaineLidocaine/Prilocaine36$383
Omeprazole26$375
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)28$366
Tamoxifen Citrate17$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$61,52849 claims
Johnson & JohnsonXarelto$441$46,53259 claims
AbbVieLinzess$733$9,96113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →